Merck

EQS-News: APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management

Retrieved on: 
Monday, June 17, 2024

APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pill combinations in the German market, continues to gear its organization towards the planned company growth and the upcoming internationalization.

Key Points: 
  • APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pill combinations in the German market, continues to gear its organization towards the planned company growth and the upcoming internationalization.
  • To this end, the Company has appointed Mila Brückel, a renowned industry expert and supply chain specialist, as Head of Supply Chain.
  • Since 3 June 2024, Mila Brückel has been responsible for all aspects of supply chain management at APONTIS PHARMA, including demand forecasting, procurement, inventory management, new product launches, and distribution to customers.
  • Bruno Wohlschlegel, CEO of APONTIS PHARMA: “Mila Brückel is a renowned expert in supply chain management in the pharmaceutical industry.

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

Retrieved on: 
Tuesday, June 11, 2024

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston.

Key Points: 
  • SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston.
  • Details of the presentation are as follows:
    Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & Formulation for Improved Bioavailability,” alongside representatives from Eli Lilly, Merck, and Novo Nordisk.
  • Selections from the presentation will be made available on the Biora Therapeutics website following the event.

OVER 1,000 HIGH SCHOOLERS GATHER ACROSS THE COUNTRY FOR A STEM AND CAREER EXPLORATION EVENT

Retrieved on: 
Thursday, June 6, 2024

This transformative conference will serve over 1,000 underrepresented high school students, equipping them with essential skills for success in college, their careers, and beyond.

Key Points: 
  • This transformative conference will serve over 1,000 underrepresented high school students, equipping them with essential skills for success in college, their careers, and beyond.
  • In addition, students will tackle real-world challenges through STEM case studies, enhancing their problem-solving abilities, teamwork, and critical thinking skills.
  • "Our National Career Academy provides INROADS scholars with the opportunity to plan their future with intention by exploring career paths," said Andrea Johnson-Lee, National Director of INROADS College Links.
  • By fostering a culture of exploration and innovation, we are shaping the next generation of leaders and change-makers."

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Retrieved on: 
Thursday, June 6, 2024

IRVINE, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the publication in Nature Medicine of final results from the Company’s CORE-001 Phase 2 trial of cretostimogene plus pembrolizumab in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NIMBC). The article, titled “Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial” is now available online and will be published in a future print issue of Nature Medicine. The most recent data cut as of May 17, 2024, was also featured as a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • “The CORE-001 trial results published in Nature Medicine clearly demonstrate the potential for cretostimogene to be used as a bladder-sparing backbone therapy for NMIBC,” said Vijay Kasturi, MD, Chief Medical Officer, CG Oncology.
  • Of the patients in a CR at 12 months, 95% of patients (19/20) maintained a CR for another 12 months.
  • The combination of cretostimogene and pembrolizumab received FDA Breakthrough Therapy Designation in May 2023.
  • To learn more about the results from BOND-003 you may read the Company’s press release issued on May 3, 2024.

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Retrieved on: 
Wednesday, June 5, 2024

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024.

Key Points: 
  • REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024.
  • Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies.
  • Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility.
  • “We are delighted to welcome Rita to our Board, and are confident that her impressive experience in finance, accounting, and operational transformation will be invaluable to Coherus,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer.

Generate:Biomedicines Expands Board of Directors with the Appointment of Rupert Vessey, M.D., Ph.D., and Nancy Simonian, M.D.

Retrieved on: 
Thursday, June 13, 2024

Generate:Biomedicines today announced the appointment of Rupert Vessey, M.D., Ph.D., and Nancy Simonian, M.D., to its Board of Directors.

Key Points: 
  • Generate:Biomedicines today announced the appointment of Rupert Vessey, M.D., Ph.D., and Nancy Simonian, M.D., to its Board of Directors.
  • Her experience and leadership in company building and advancing clinical programs will greatly enhance the company’s efforts to deliver next-generation therapeutics.
  • “We are thrilled to welcome Rupert and Nancy to our Board,” said Mike Nally, Chief Executive Officer of Generate:Biomedicines and CEO-Partner, Flagship Pioneering.
  • Together, they will enhance our ability to leverage cutting-edge science to more swiftly deliver better medicines to patients.”

Global Trispecific Antibodies Clinical Trials & Market Outlook 2024, with Competitive Insight on 18 Companies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 11, 2024

The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering.
  • Global Trispecific Antibodies Clinical Trials & Market Outlook 2024 Report Highlights:
    Trispecific Antibodies in Clinical Trials: > 50 Antibodies
    Majority of Antibodies Developed for Multiple Myeloma: 8 Antibodies
    Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
    China Dominating Trispecific Antibodies Clinical Trials: >20 Antibodies
    The blueprint in the domain of immunotherapy has perceived futuristic with the advent of antibody founded therapy, like monospecific and bispecific antibodies, in the past decenniums.
  • To date, no trispecific antibody have been launched in the market; however, it is probable that handful of trispecific antibodies will be approved in the imminent years.
  • At present, more than 50 trispecific antibodies are lately in the preclinical together with clinical studies for the treatment of cancer, infectious diseases, and eye diseases.

Global Animal Health Market (Feed Additives, Pharmaceuticals & Vaccines): Insights & Forecast 2024-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 10, 2024

The "Global Animal Health Market (Feed Additives, Pharmaceuticals & Vaccines): Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Animal Health Market (Feed Additives, Pharmaceuticals & Vaccines): Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The global animal health market is expected to record a value of US$64.71 billion in 2028, growing at a CAGR of 6.31% for the period spanning 2024-2028.
  • Based on product type, the global animal health market can be segmented into feed additives, pharmaceuticals and vaccines.
  • The report provides a comprehensive analysis of the global animal health market along with the focus on feed additives, pharmaceuticals and vaccines market.

Insights From Global Life Sciences Benchmarking: Experts and End Users to Discuss Emerging Trends and Benefits

Retrieved on: 
Monday, June 10, 2024

Linesight , a global construction consultancy will host its first in-person Life Sciences Capital Project Benchmarking event in Boston at the Fairmont Copley Plaza on June 17 at 4:00 PM.

Key Points: 
  • Linesight , a global construction consultancy will host its first in-person Life Sciences Capital Project Benchmarking event in Boston at the Fairmont Copley Plaza on June 17 at 4:00 PM.
  • The event will feature a panel of experts who will provide life sciences professionals with an overview of the transformative benefits of benchmarking capital projects and share high-level insights from an analysis of 213+ global projects valued at $35 billion.
  • “The life sciences industry in New England is one of the world’s most dynamic and exciting,” said Linesight’s Barry Enright, Director and Boston office lead.
  • They are aiming for maximum efficiency and recognize that visibility into comparable data from peers is essential in planning and managing a capital project.”

Nimble Announces Formation of a World-Class Scientific Advisory Board

Retrieved on: 
Tuesday, June 11, 2024

Nimble Therapeutics today announced the formation of the Nimble Scientific Advisory Board (SAB) to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.

Key Points: 
  • Nimble Therapeutics today announced the formation of the Nimble Scientific Advisory Board (SAB) to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.
  • “We are honored to have these extraordinary scientific leaders join Nimble in its mission to create oral therapeutics to treat patients with immune-mediated diseases,” said Pete Gough, CSO of Nimble Therapeutics.
  • Luisa is a member of the Scientific Advisory Board of Anaptys, GPCR, Imimidomics and Attovia, and was previously on the SAB of Prometheus, Ambrx and Ventyx Bio and on the Board of Directors of Jounce Therapeutics.
  • Previously, Tomi was a Distinguished Scientist at Merck & Company, Founding Chief Scientific Officer at Aileron Therapeutics and Senior Vice-President of Drug Discovery at Ariad Pharmaceuticals (now Takeda).